Novo Nordisk
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments.
NVO Key Statistics
Stock Snapshot
With a market cap of 195.45B, Novo Nordisk(NVO) trades at $44.45. The stock has a price-to-earnings ratio of 13.85 and currently yields dividends of 2.6%.
On 2025-11-24, Novo Nordisk(NVO) stock moved within a range of $41.45 to $47.84. With shares now at $44.45, the stock is trading +7.2% above its intraday low and -7.1% below the session's peak.
Trading activity shows a volume of 36.38M, compared to an average daily volume of 17.96M.
Over the past 52 weeks, Novo Nordisk(NVO) stock has traded between a high of $112.52 and a low of $41.45.
Over the past 52 weeks, Novo Nordisk(NVO) stock has traded between a high of $112.52 and a low of $41.45.
NVO News
Novo Nordisk (NVO) is down -8.7%, or -$4.14 to $43.49. TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research too...
Stock futures are modestly positive, but there remain lingering concerns around growth, tech valuations and incomplete data. Equity markets are showing tentativ...
Below is Validea's guru fundamental report for NOVO NORDISK A/S (ADR) (NVO). Of the 22 guru strategies we follow, NVO rates highest using our Patient Investor m...
Analyst ratings
59%
of 32 ratingsMore NVO News
Shares of Novo Nordisk (NVO) were down nearly 10% in pre-market hours on Monday after the pharmaceutical company said its highly anticipated Alzheimer’s drug tr...
Novo Nordisk A/S (NYSE:NVO) stock fell on Monday after the company released topline results from the 2-year primary analysis of evoke and evoke+ phase 3 trials...
...
Trials didn’t confirm the superiority of semaglutide compared with placebo in reducing Alzheimer’s disease. Tom Ittle/Reuters Novo Nordisk NOVO.B -9.80 %decrea...
Novo Nordisk sinks after Ozempic’s key ingredient fails to slow down Alzheimer’s in trials Novo Nordisk is down nearly 9% in trading in Europe, with its US-lis...
Shares in Novo Nordisk, the Danish maker of Ozempic and Wegovy, tumbled after studies showed the active ingredient in its hit weight-loss drugs didn't slow the...
Novo Nordisk (NYSE:NVO) shares have edged slightly higher today, drawing interest from investors tracking subtle market movements. The mild stock uptick comes a...
